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The efficacy of conventional ocular formulations is limited by poor corneal retention and permeation, 
resulting in low ocular bioavailability. Mucoadhesive chitosan (CS)/ tripolyphosphatesodium (TPP) and 
chitosan (CS)/ tripolyphosphatesodium (TPP)-alginate (ALG) nanoparticles were investigated for the 
prolonged topical ophthalmic delivery of ofloxacin. A modified ionotropic gelation method was used 
to produce ofloxacin-loaded nanoreservoir systems. The ofloxacin-loaded CS/TPP and CS/TPP-ALG 
nanoparticles were characterized for particle size, morphology, zeta potential, encapsulation efficiency, 
subsequent release and corneal penetration study. The designed nanoparticles have a particle size from 
113.8 nm to 509 nm and zeta potential from 16.2 mV to 40.3 mV and encapsulation efficiency values 
ranging from 19.7% to 33.1%. Nanoparticles revealed a release during the first hours, followed by a more 
gradual drug release. The ofloxacin-loading CS/TPP or CS/TPP-ALG NPs developed are pronounced 
penetration enhancing effect as compared to OFX solution (5-6.5 times). Thus, these nanoparticles have 
a strong potential for ocular drug delivery.
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INTRODUCTION
Infections of the eye are caused by a number of 
different organisms and require effective treatment to avoid 
further complications and vision loss. Systemic treatment 
is not ideal due to systemic side effects and the low ocular 
bioavailability of the drug (Duxfield et al., 2016). The 
eye is a unique organ for drug delivery. According to 
the eye’s physiology and anatomy, a small percentage of 
prescription drug was absorbed, because the protection 
mechanisms, such as tearing, blinking reflex and tears 
streaming from the eyes, are expelled (Thakur, Kashiv, 
2011). About 5% of the eye drugs in the cornea reaches the 
intraocular tissues, while a major fraction of the instilled 
dose is often absorbed systemically via the conjunctiva and 
nasolacrimal duct (Lang, 1995). The more topical aqueous 
solution and suspension forms after use impair vision. 
But a rapid and short-input entry of some drugs into the 
systemic circulation is unavoidable, and this formulation 
is quickly diluted by the tear layer (Nagarwal et al., 2009). 
Nowadays, more sensitive diagnostic techniques and novel 
therapeutic agents are used to provide ocular delivery 
systems with high therapeutic efficacy. Nanoparticles 
show a better application as compared to conventional 
delivery systems (Das, Suresh, 2010). Proposed polymer 
nanoparticles are reported to be devoid of any irritant 
effect on the cornea, iris, and conjunctiva, and thus appear 
to be suitable inert carriers for ophthalmic drug delivery. 
Specific nanocarriers can interact with the ocular mucosa, 
thereby increasing the retention time of drug in the eye, 
and its permeability across the cornea and conjunctiva 
(Reimondez-Troitiño et al., 2015). Taking into account 
this information and also the fact that the cornea and 
conjunctiva have a negative charge, it was thought that 
the use of mucoadhesive polymers that might interact 
intimately with these extra ocular structures would 
increase the concentration and residence time of the 
associated drug (Sahoo, Dilnawaz, Krishnakumar, 2008). iD
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Among the mucoadhesive polymers investigated until 
now, the cationic polymer chitosan (CS) has attracted a 
great deal of attention because of its unique properties, 
such as acceptable biocompatibility and biodegradability 
(Hirano et al., 1988) as well as the ability to increase 
membrane permeability (Aspden et al., 1997; Takeuchi et 
al., 1996). The substrate specificities of lysozyme in the 
degradation of soluble chitosan are rather independent for 
pH between 4.5 and 7, and it may be inferred that these 
substrate specificities also operate in vivo at physiological 
conditions (Vårum et al., 1997). The interaction and 
prolonged residence time of CS nanoparticles at the ocular 
mucosa of rabbits have been reported, and it was shown 
that following topical instillation of fluorescence-labelled 
nanoparticles, these colloidal drug carriers remained 
attached to the cornea and the conjunctiva for at least 24 
h (De Campos, Sánchez, Alonso, 2001). The presence 
of CS in an ophthalmic solution resulted in a significant 
increase of the precorneal residence time of antibiotic 
drugs when compared with commercial drug solutions 
(Felt et al., 1999). Ofloxacin and chitosan alone have 
an antimicrobial effect against both gram-positive and 
gram-negative bacteria, but complexation (CS-OFX) 
is better enhanced by the antimicrobial activity (Singh, 
Dutta, 2010). Sodium alginate was chosen as a vehicle 
for ophthalmic formulations since it exhibits several 
favourable biological properties such as biodegradability 
and non-toxicity. A prolonged precorneal residence of 
formulations containing alginic acid was looked for, not 
only because of its ability to gel in the eye, but also due to its 
mucoadhesive properties (Sechoy et al., 2000). Ofloxacin 
was successfully formulated as an ion-activated in situ 
gel forming ophthalmic solution using sodium alginate 
in combination with Hydroxy Propyl Cellulose (HPC) 
as a viscosity enhancer, which sustained the drug release 
over a period of 8 h (Abraham et al., 2009). Chitosan–
alginate (CS–ALG) polyionic complexes protecting the 
encapsulate limit the release of encapsulated materials 
more effectively than either alginate or chitosan alone 
(Yan, Khor, Lim, 2001). Ofloxacin is as an agent against 
external ocular infections, and is exceptionally potent 
against a wide range of gram-positive and gram-negative 
bacteria and obligate anaerobes. It is effective in vitro 
against many organisms that cause ocular infections, for 
example haemophilus influenzae, neisseria gonorrhoeae, 
staphylococcus species, streptococcus species and 
pseudomonas aeruginosa, which are associated with 
ocular infections that are especially serious and difficult to 
treat (Bron et al., 1991). The excellent activity of ofloxacin, 
its broad spectrum of activity, its high tear concentrations, 
and its reported clinical efficacy all support its potential 
use as a treatment for ocular bacterial infections (Osato et 
al., 1989). The current study is aimed at developing and 
optimizing a mucoadhesive nanoparticulate formulation 
of ofloxacin for ocular delivery. 
MATERIAL AND METHODS
Material
Low molecular weight chitosan (CS) with a degree 
of deacetylation of 85% and tripolyphosphate sodium 
(TPP) obtained from Sigma-Aldrich (USA). Acetic acid at 
100% was purchased from Merk (Darmstadt, Germany). 
The medium viscosity sodium alginate (ALG) was 
purchased from Sigma-Aldrich (USA). Ofloxacin (OFX) 
was provided Exir (Lorestan, Iran). Sodium hydroxide 
(NaOH) and hydrochloric acid (HCl) were from Merk 
(Darmstadt, Germany). Methanol and triethylamine were 
of analytical grade and purchased from Merck (Darmstadt, 
Germany). All other materials and reagents were of the 
highest grade commercially available.
Methods
Preparation of Nanoparticles without ALG (Chitosan/ 
tripolyphosphatesodium nanoparticles)
Chitosan/tripolyphosphatesodium nanoparticles 
(CS/TPP NPs) were prepared by an ionic gelation method 
as reported by Calvo et al. (1997) with some modifications. 
CS was dissolved in acetic acid (1% v/v) to obtain the 
cationic phase (100 mL) in different concentrations. CS-
NPs were obtained upon the addition of 2 mL of TPP 
solution in two respective final concentrations (0.5 and 
0.75 mg/mL) by drop-wise to 5 mL of chitosan solution 
under magnetic stirring (1000 rpm) at room temperatures 
for 20 min. The experimental flow sheet is shown in Figure 
1. For the preparation of OFX-loaded nanoparticles, 100 
mg of ofloxacin was dissolved in the cationic phase (100 
mL) and the final nanoparticle suspension was prepared 
as described earlier. In order to achieve the final OFX:CS 
mass ratios of 1:0.5, 1:1.5, 1:3.5, and 1:5, four formulations 
(Fa, Fb, Fc and Fd) with different concentrations of CS and 
TPP were prepared as shown in Table I.
Preparation of nanoparticles with ALG (chitosan/
tripolyphosphatesodium-alginate) nanoparticles)
The sodium alginate solutions in concentration 
(0.05, 0.1, 0.25 and 0.5 mg/mL) were prepared by 
dissolving the polymer in 100 mL of TPP solution in 
concentration (0.75 mg/mL). Ofloxacin-loaded NPs were 
formed spontaneously upon drop-wise addition of 2 mL of 
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TPP-ALG solution to 5 mL of chitosan solution (1.5, 3.5 
mg/mL) containing ofloxacin (1 mg/mL) with magnetic 
stirring (1000 rpm) for 20 min at room temperature. In 
order to achieve final OFX:Polymers mass ratios of 1:1.54, 
1:1.54, 1:3.6, 1:3.7, four formulations (Fe, Ff, Fg and Fh) 
with different Cs/TPP/ALG mas ratio were prepared as 
shown in Table I.
Collecting of solid state chitosan particulate by freeze 
drying
The nanoparticle suspensions centrifuged at 30,000 
rpm for 30 min (Beckman Coulter centrifuges, optima-
L90k, USA), were used respectively. The nanoparticles 
were removed, and these suspensions were frozen and 
then freeze-dried (Christ Freeze Dryer ALPHA 2-4, PLUS, 
GERMANY). The dried residues were stored at 4°C until 
analysis.
Determination of encapsulation efficiency 
and the particles’ drug content
The encapsulation efficiency of OFX-loaded NPs 
was calculated as the difference between the total amount 
of ofloxacin used to prepare the nanoparticles and the 
amount of ofloxacin present in the supernatant after 
centrifugation of the nanoparticle suspensions (Wu et al., 
2005). The amount of drug was determined by an HPLC 
method as described in the section of HPLC method. 
The drug content (DC) and the encapsulation efficiency 
(EE) were calculated by using the following equations 
(Equations (1) and (2) respectively):
 (1)
 (2)
Particle size, PDI and zeta potential 
measurements
The particle size and the zeta potential of the freshly 
prepared NPs were determined by photon correlation 
spectroscopy and laser-doppler anemometry by using a 
Malvern Zetasizer, and the nanoparticle suspensions were 
analysed at 25 ºC. Each sample was measured three times, 
after which the average value was considered for the data 
analysis of zeta potential.
HPLC method
Chromatographic separations were performed 
by using a Shimadzu (model LC-10ADvp) liquid 
chromatography connected to a UV–VIS detector (model 
SPD-M10Avp) and to a ChromatoPlus computerized 
integration system (Shimadzu Corporation, Kyoto, Japan). 
Manual injections of the samples were performed by using 
a Rheodyne7725 injector with a 20 µL sample loop. The 
analytical column (250×4.6 mm I.D.) was packed with 
C18 (5 μm particle size) by MZ-Analysentechnik (Mainz, 
Germany). Methanol and triethylamine 0.1% (TEA 0.1%) 
buffer at pH 3.0 with phosphoric acid (10:90 v/v) were 
used as the mobile phases (flow rate of 1.2 mL/min). 
Ultraviolet detection was set at 293 nm and the elution 
time was 2.4 min.
Stability of nanoparticles
To understand the stability of nanoparticles in 
suspension, two formulations of nanoparticles Fc and 
Fg were chosen after their preparation, nanoparticle 
suspension was lyophilized using 5% mannitol as a 
cryoprotectant. Dry nanoparticles were suspended in 
phosphate buffer saline; particle size, and zeta potential 
measurements were performed. Freeze-dried samples, 
stored at room temperature, were rehydrated with the 
FIGURE 1 - The experimental procedure.
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original volume of ultrapure water to restore the drug and 
polymer concentrations at every 30 days interval and the 
particle size and zeta potential measurements were taken. 
Three measurements of particle size and zeta potential 
were performed and used in statistical analysis of the data 
(Agnihotri, Aminabhavi, 2007; Motwani et al., 2008)
Fourier transform infrared (FTIR) spectral studies
FTIR spectra were obtained by using an FTIR-
spectrometer (Shimadzu IR PRESTIGE-21., Japan). 
The samples were dried in a vacuum desiccator, mixed 
with micronized KBr powder and compressed into 
discussing a manual tablet press. The FTIR spectra of 
pristine ofloxacin, ALG, Chitosan, Chitosan/TPP NPS and 
Chitosan/TPP-ALG nanoparticles were obtained.
Thermo-gravimetric studies
TGA analysis was obtained using (STA 503, BAHR, 
Germany). 5.0 mg of the freeze-dried powder samples 
crimped in a standard platinum pan and heated from 20 to 
500 ºC with a nitrogen flow rate of 6 L.h-1 and a heating 
rate of 10ºC/min.
Scanning Electron Microscopic (SEM) Studies
Scanning electron microscopy (SEM) was used to 
observe the morphology of the nanoparticles. The NPs 
were dried at room temperature and placed on metal stubs 
with adhesive tape, sputter coated with gold and then 
observed under a scanning electron microscope (KYKY, 
EM-3200, China) operating in high vacuum moderated at 
an accelerating voltage of 20 kV.
Drug release study
To detect the amount of drug released from the 
nanoparticles, an appropriate amount of sample (estimated 
to contain approx. 5 mg of NPs or ofloxacin control 
solution) was introduced into an acceptor compartment 
containing 1 mL of phosphate buffer at pH 7.4 with sink 
condition, respectively, separated by a dialysis membrane 
(Mw cut-off= 12,000–14,000 Daltons; Delchimica 
Scientific Glassware, Milan, Italy), as illustrated in 
Figure 2(A), from the receptor compartment containing 
9 mL of the same aqueous buffer. The system was stirred 
continuously at 100 rpm maintained at 37°C. The receptor 
compartment was closed to prevent evaporation losses 
from the dissolution medium as shown in Figure2(C). A 
certain amount of sample aliquot was withdrawn at regular 
time intervals and the same volume was replaced with a 
fresh buffer and the drug concentration was quantified 
in the acceptor phase by high performance liquid 
chromatography (HPLC) following the method previously 
described in the section of HPLC method.
Ofloxacin penetration study through isolated 
sheep corneas
Corneal and conjunctival epithelia are the key 
tissues in topical ocular absorption of drugs. These tissues 
contain tight junctions that limit the paracellular drug 
(Maurice, Mishima, 1984). Cornea is a tight barrier for 
drug absorption. Permeability of the corneal epithelium 
is 10−7–10−5 cm/s and the bioavailability of ocular 
administration is very low (Urtti et al., 1990). In addition, 
the corneal epithelium have mucus layer on their surface 
which protects all wet epithelial surfaces. 
For the penetration study, using excised sheep 
corneas. Within 1 h after the euthanasia, a small transverse 
incision was made about 5 mm from the limbus, and 
subsequently the cornea with the scleral ring was 
carefully cut out. Forceps were used to delicately remove 
the lens first and then the iris, with the cornea being left 
as a transparent film. The cornea was then mounted as 
maintained on the cornea curvature. A volume of 1 mL 
PBS (pH 7.4) with 5 mg NPs or OFX control solution 
were added first in the acceptor compartment, as shown 
in Figure 2(B), at 37°C to and then the cornea was fixed 
in and the epithelial side was immersed in PBS at the 
receptor compartment. A certain amount of samples were 
taken from the receptor compartment at certain intervals 
FIGURE 2 - The acceptor compartment for drug release (A), 
the acceptore compartment for penetration studies (B), receptor 
compartment (C).
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and then the sample volume was immediately replaced 
with an equal amount of PBS buffer, in order to maintain 
receptor compartment conditions. The amount of OFX 
in the acceptor was determined by using the HPLC 
method as described in the section of HPLC method. The 
code of ethics approved for this project is IR.KUMS.
REC.1395.216. 
Calculation of permeability coefficients
The apparent corneal permeability coefficient (Papp, 
cm.s-1) was determined according to
Papp=ΔQ/ΔtAC0 
where Q is the total amount permeated at time t, ΔQ/Δt 
(the slope of the linear portion of the graph) is the steady-
state flux of ofloxacin to the receiver side (μg/min), A is 
the corneal surface area (in this study 1 cm2) and C0 is 
the initial donor side drug amount (μg/mL) (Calvo et al., 
1996).
When the steady-state portion of the drug permeated 
VS time graph is extrapolated, the point of intersection at 
the time axis gives the lag time of permeation (tL). This 
is the time required to establish a steady concentration 
gradient within the membrane separating the donor from 
the receptor compartment.
RESULTS AND DISCUSSION
Preparation of CS/TPP and CS/TPP-ALG 
nanoparticles
In this study, we described the preparation of a 
chitosan nanoparticulate system that is able to incorporate 
ofloxacin, with appropriate mucoadhesiveness and 
antimicrobial characteristics for the treatment of ocular 
infections. Chitosan nanoparticles were produced by 
inotropic gelation, a method based on the formation of 
complexes between chitosan and TPP or chitosan and TPP-
ALG, under mild conditions. In this method, nanoparticles 
are formed spontaneously upon mixing of CS and TPP or 
TPP-ALG solutions, through the formation of inter- and 
intra-molecular linkages between the phosphate groups of 
TPP and the amino groups of Chitosan (Fan et al., 2012) 
and interactions between the carboxyl groups of alginate 
and the amine groups of chitosan (Yan, Khor, Lim, 2001).
As reported in the literature, the formation process of the 
nanoparticles is influenced by a number of parameters 
such as CS,TPP and ALG concentrations, and the time and 
rate of mixing. Therefore, preliminary experiments were 
performed to optimize CS/TPP and CS/TPP-ALG ratios 
for nanoparticle preparation through visual observation 
of the dispersions and size testing. Finally, the various 
formulations with different mass ratios of CS/TPP or CS/
TPP-ALG were prepared as shown in Table I.
Determination of particle size, PDI and zeta 
potential
The size, polydispersity index (PDI) and zeta 
potential of NPs are reported in Table II. The mean 
particle size was in the range of 113−509 nm. The 
particle size, as previously reported by Calvo et al., 
(Calvo, Remunan‐Lopez et al., 1997), depends on the 
CS concentration. The minimum size corresponds to 
the lowest CS concentration (Fa). On the other hand, 
the size of the particles was affected by the Alginate 
concentration (Motwani, Chopra et al., 2008), with 
the size being smaller for lower ALG concentration. 
These results confirm that smaller NPs are the result, 
when the availability of the functional groups on two 
TABLE I - Preparative characteristics of the different formulations
Formulation CS (mg/mL) TPP (mg/mL) ALG (mg/mL) CS:TPP  mass ratio
Fa 0.5 0.5 _ 1:0.4
Fb 1.5 0.5 _ 1:0.13
Fc 3.5 0.75 _ 1:0.086
Fd 5 0.75 _ 1:0.06
Fe 1.5 0.75 0.05 1:0.2
Ff 1.5 0.75 0.1 1:0.2
Fg 3.5 0.75 0.25 1:0.086
Fh 3.5 0.75 0.5 1:0.086
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polymers for interaction is in stoichiometric proportion. 
The zeta potential of the nanoparticles ranged between 
+16.2 and +40.3 mV, which shows a dependency on 
the concentration of CS. A gradual increase in the zeta 
potential was noted with the increase in CS concentration 
and the reduction in ALG concentration. It can be 
ascribed to the higher availability of protonated amine 
groups with increasing CS concentration. There is no 
relationship between CS concentration and PDI of the 
nanoparticles that were formed by CS and TPP. However, 
the PDI of NPs were increased by increasing alginate 
concentration in CS/ TPP-ALG nanoparticles (Table II).
Determination of encapsulation efficiency and 
the particles’ drug content
The observations for encapsulation efficiency (%) 
and the particles’drug content (%) are presented in 
Table II. The increasing concentration of CS from 
0.5 mg/mL to 1.5 mg/mL at a constant TPP and drug 
concentration caused a great increase in the encapsulation 
of ofloxacin into CS/TPP nanoparticles from 19.78% to 
28.62%, and the increasing concentration of CS from 
3.5 mg/mL to 5 mg/mL also caused a great increase in 
the encapsulation efficiency from 24.06% to 33.1%. 
This indicates that less amount of nanoparticles were 
formed due to the lower chitosan concentration. It 
was also observed by Motwani et al. (2008) that the 
encapsulation of gatifloxacin into CS/ALG nanoparticles 
was highest when CS and ALG were used at intermediate 
concentrations, whereas the encapsulation was found 
to be fewer when either CS or ALG was used at higher 
concentration levels (Motwani et al., 2008).
Also, the CS/TPP-ALG nanoparticles showed a 
slight increase in encapsulation efficiency and drug content 
with respect to that of CS/TPP nanoparticles. This could 
be due to an increase in crosslink density, which might 
prevent the leaching of drug particles during the formation 
of nanoparticles.
Morphology
Morphological characterizations via scanning 
electron microscopy (Figure 3) showed nanoparticles 
exhibiting rounded and some oblate shapes. The shapes 
of the particles were approximate to spheres, and were 
smooth with almost homogeneous structures. Moreover, 
the nanoparticles tended to agglomerate probably due 
to the experimental conditions used for the preparation 
of NPs. CS/TPP NPs were nearly spherical in shape and 
smaller in size (Figure 3A), while these nanoparticles’ 
structure took a regular shape and larger size after addition 
of ALG (Figure 3B).
Identification of nanoparticles constituents
CS, ALG, ofloxacin, CS/TPP nanoparticles, and 
CS/TPP-ALG nanoparticles were analysed using an FTIR 
spectrophotometer for characteristic absorption bands, 
indicating their interactions (Figure 4). The FTIR spectrum 
of CS shows characteristic peaks at ~1072 cm-1 (due to the 
presence of -CO groups) and at ~3400 cm-1 (representing 
the presence of OH groups) and at ~1600 cm-1 in the CS 
spectra due to the –NH2 groups of CS. In the IR spectrum 
of the CS/TPP and CS/TPP-ALG nanoparticles, this peak 
shifted from ~ 1600 cm-1 to 1624 cm-1, thus confirming 
that amino groups were involved in the cross-linking 
by phosphate. The IR spectrum of ofloxacin showed its 
characteristic peaks at ~1000 cm-1for C-F,1712 cm-1 for 
C=O, and 3425 cm-1 for OH (Sahoo et al., 2012). The 
shift of the C=O peak at1712 cm-1 confirmed the presence 
of ofloxacin inside both the CS/TPP and CS/TPP-ALG 
TABLE II - Properties of the different formulations (mean ± SD, n = 3)
Formulation Size (nm) PDI Zeta Potential (mv) EE% DC%
Fa 113.8±2.3 0.252±0.08 16.2±3.6 19.78± 0.13 19.78±0.19
Fb 165.5±3.9 0.257±0.23 23.8±2.7 28.62±0.21 23.85±0.23
Fc 287.4±4.6 0.242±0.19 30.6±2.1 24.06±0.16 15.32±0.17
Fd 396.1±2.9 0.254±0.11 40.3±1.8 33.1±0.22 16.32±0.09
Fe 227.6± 1.6 0.313±0.17 28.1±1.2 29.88±0.53 28.46±0.14
Ff 243.1±4.3 0.373±0.32 32.4±3.2 29.77±0.34 23.63±0.1
Fg 439.8± 1.9 0.39±0.14 37.4±1.7 24.82±0.43 18.66±0.08
Fh 509±5.2 0.423±0.28 35.3±2.6 22.95±0.24 17.08±0.09
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nanoparticle structure. The IR spectrum of ALG showed 
its characteristic peaks at 3425 cm-1 for OH, 948 cm-1 
for O-H bend (out-of-plane) and 1419 cm-1 and 1616 
cm-1 for symmetric and asymmetric stretching of COO- 
(Papageorgiou et al., 2010). The disappearance of peaks 
at 1419 cm-1 and 1616 cm-1, and also the observation of 
the peak at 1490 cm-1in the FT-IR spectrum of CS/TPP-
ALG nanoparticles was attributed to the ionic interactions 
between the carboxyl groups of alginate and the amine 
groups of chitosan.
Thermo-gravimetric studies
The TGA curves of pristine ofloxacin, CS, ALG, 
CS/TPP NPS and CS/TPP-ALG NPS are presented in 
Figure 5. There are two distinct changes in the TG profiles 
of ofloxacin. The first weight loss from 25˚C to 150˚C may 
be due to free water evaporation. The second weight loss 
from 289˚C to 395˚C is attributed to OFX decomposition. 
In the curves of CS, the first weight loss from 25˚C to 
100˚C may be attributed to free water evaporation. The 
FIGURE 3 - Scanning electron micrographs of Chitosan /TPP NPs (A), Chitosan /TPP-Alginate NPs (B), bar represent 1 μm.
FIGURE 4 - FTIR spectrum: Chitosan (A); Alginate (B); Ofloxacin (C); Chitosan/TPP nanoparticles (D); Chitosan/TPP-Alginate 
nanoparticles (E).
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second weight loss from 273˚C to 303˚C may be due to CS 
decomposition. In the curves of ALG, the weight loss from 
235˚C to 275˚C corresponds to the decomposition of ALG. 
The other weight losses are the same as those of ofloxacin 
and CS. The TG patterns of CS/TPP NPs are shown in 
Figure 6(D). The weight loss from 223˚C to 296˚C may 
be attributed to the destruction of ionic bond between CS 
and TPP and disintegrated nanoparticles. We can see that 
disintegrated nanoparticles come out around 249˚C to 
348˚C in Figure 6(E), which may be explained by the fact 
that the ALG is partly encapsulated into the nanoparticles. 
The last weight losses from 309˚C to 451˚C in Figure 6(D) 
and from 353˚C to 464˚C in Figure 6(E) may be due to the 
destruction of drug decomposition.
In vitro ofloxacin release study
The results of OFX release from CS nanoparticles 
are summarized in Figure 6. For Fc formulation, more 
than 50% of drug content (% 53/5) was released in 10 h 
with the drug release peak in 20 h, and a small amount of 
OFX was released after 20 to 66 h. In 7 hours, the drug 
content of Fg was released (52.9%), and reached 73.1% 
within 17 h of release. Both formulations had amounts of 
residual drug up to 66 h. Comparative release indicated 
that chitosan nanoparticles were capable of releasing 
the drug for a long time, which this could be due to the 
structural strength of chitosan nanoparticles in the coating. 
The result demonstrated sustained/prolonged drug release 
from ofloxacin-loading CS/TPP or CS/TPP-ALG NPs.
Ofloxacin penetration study through isolated 
sheep corneas
The efficacy of nanoparticles to increase corneal 
penetration was assessed by measuring the transcorneal 
flux of the drug through isolated sheep cornea. Figure 
7 shows the amount of OFX permeated from the NPs 
formulation and from the same concentration of OFX in 
solution. The results indicate that the OFX permeability 
coefficients in solution were 3.77 and 3.43 (*10-4 cm.s-) 
for OFX in solution and OFX in chitosan solution, which 
have no significant difference. This is because of the tight 
junctions among corneal epithelial cells. Also lag time for 
OFX in chitosan solution and OFX solution were 17 and 
32 h respectively. 
The percentage of drug penetration in Fc after 
48 hours and in Fg after 40 hours has reached steady 
state. Nanoparticles formulation produced Papp, 18.9 and 
25.45 (*10-4 cm.s-1) for Fc and Fg, which were 5 and 6.7 
times more than OFX in solution. This can be explained 
by the fact that Fg and Fc penetrated to the corneal surface 
by both electrostatic force and hydrogen bonds. On the 
other hand, the polycationic Fg and Fc could improve 
the permeability of cornea by opening the tight junctions 
among corneal epithelial cells, which was similar to the 
case of chitosan (Di Colo et al., 2004). In vivo experiments 
by M. De Campos et al. following topical instillation 
of CyA-loaded CS nanoparticles to rabbits, observed 
therapeutic concentrations in external ocular tissues (i.e., 
cornea and conjunctiva) during at least 48 h (De Campos, 
Sánchez, Alonso, 2001). Ocular penetration enhancers 
such as benzalkonium chloride, non-ionic surfactants, bile 
salts and EDTA have been widely investigated (Sultana 
et al., 2006), due to their nonspecific actions that include 
permanent damage to the ocular membranes and tight 
junction, and so they have a low safety profile.
Stability
For long-term storage of nanoparticles, aqueous 
solutions of the nanoparticles are basically required to be 
lyophilized powder as products and it must be reconstituted 
FIGURE 5 - TGA curves of Ofloxacin (A); Chitosan (B); 
Alginate (C); Chitosan/TPP nanoparticles (D); Chitosan/TPP-
Alginate nanoparticles (E).
FIGURE 6 - In vitro release profile of ofloxacin from Chitosan/
TPP nanoparticles (Fc); Chitosan/TPP-Alginate nanoparticles 
(Fg). Release assay was performed in PBS solution, pH: 7.4, at 
37 °C with agitation (n=3).
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into physiological solution similar to its original aqueous 
solution immediately before use (Motwani et al., 2008). 
Figure 8 (CS/TPP) and Figure 9 (CS/TPP-ALG) show 
the change in particle size and the zeta potential of 
reconstructed nanoparticles suspension, after storage for 
a period of six months at room temperature. It showed 
that the size increased and the amount of zeta potential 
decreased depending on time because of the aggregation 
of particles. 
CONCLUSION
Ofloxacin, a second generation fluoroquinolone, 
TABLE III - Permeability coefficients and lag time 
Formulation Papp (×10-4) (cm/s) tL (h)
Ofloxacin solution 3.77±0.235 32
Ofloxacin solution in chitosan 3.43±0.311 17
Fc 25.45±1.56 < 1
Fg 18.9 ±0.560 < 1
FIGURE 7 - In situe penetration profile of ofloxacin from Chitosan/TPP nanoparticles (Fc); Chitosan/TPP-Alginate nanoparticles 
(Fg); ofloxacin in chitosan solution; ofloxacin solution. Penetration assay was performed in PBS solution, pH: 7.4, at 37°C with 
agitation (n=3).
FIGURE 8 - Particle size and zetapotential of reconstituted Fc(chitosan/TPP nanoparticles) upon storage for 6 months at room 
temperature.
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and a broad-spectrum antibacterial agent were used in 
the treatment of ocular infections, and were successfully 
formulated in the form of CS/TPP and CS/TPP-ALG 
nanoreservoir systems. 
Nanoparticles were prepared and characterized in the 
present study. Obtained nanoparticles had small particle 
size and positive surface charges, which improved good 
stability in six months. The NPs thus produced improved 
high penetration through isolated sheep cornea due to the 
interaction with negatively charged biological membranes 
and site-specific targeting in vivo. According to Calvo et 
al. (1994), the results suggest the ability of these colloidal 
carriers to specifically target drugs to the cornea while 
avoiding systemic drug loss through the conjunctiva. 
Also, nano-conjugated OFX showed an effective drug 
delivery system for penetrated biological cells (Calvo et 
al., 1994; Chakraborty et al., 2012). In conclusion, these 
coatings achieved pronounced penetration enhancing 
effect as compared to OFX solution (5-6.5 times). It is 
notable that the chitosan and chitosan/alginate coating, 
as biocompatible and biodegradable polymer, has the 
potential to be used as a non-toxic penetration enhancer 
in nanoparticle form, especially for posterior ocular 
drug delivery. In addition, the study has demonstrated 
a slower, sustained release of OFX through cornea, as 
compared to the solution formulation of this drug. Thus, 
this formulation of nanoparticles has a strong potential 
for a sustained release effect of the drug, when applied to 
the eye topically.
FIGURE 9 - Particle size and zetapotential of reconstituted Fg (chitosan/TPP-Alginate nanoparticles) upon storage for 6 months 
at room temperature.
ACKNOWLEDGEMENTS
This work was financially supported by Research 
&Technology Center of Kermanshah University of 
Medical sciences Iran, (Financial Cod 96363). 
REFERENCES
Abraham S, Furtado S, Bharath S, Basavaraj BV, Deveswaran 
R, Madhavan V. Sustained ophthalmic delivery of ofloxacin 
from an ion-activated in situ gelling system. Pak J Pharm Sci. 
2009;22(2):175-79.
Agnihotri SA, Aminabhavi TM. Chitosan nanoparticles for 
prolonged delivery of timolol maleate. Drug Dev Ind Pharm. 
2007;33(11):1254-62.
Aspden TJ, Mason JD, Jones NS, Lowe J, Skaugrud O, Illum 
L. Chitosan as a nasal delivery system: the effect of chitosan 
solutions on in vitro and in vivo mucociliary transport rates in 
human turbinates and volunteers. J Pharm Sci. 1997;86(4):509-
13.
Bron AG, Leber G, Rizk SN, Baig H, Elkington AR, Kirkby 
GR, et al. Ofloxacin compared with chloramphenicol in the 
management of external ocular infection. Br J Ophthalmol. 
1991;75(11):675-79.
Preparation and characterization of novel, mucoadhesive ofloxacin nanoparticles for ocular drug delivery
Braz. J. Pharm. Sci. 2019;55:e17105 Page 11 / 12
Calvo P, Alonso MJ, Vila-Jato JL, Robinson JR. Improved ocular 
bioavailability of indomethacin by novel ocular drug carriers. J 
Pharm Pharmacol. 1996;48(11):1147-52.
Calvo P, Remunan‐Lopez C, Vila-Jato JL, Alonso MJ. Novel 
hydrophilic chitosan‐polyethylene oxide nanoparticles as 
protein carriers. J Appl Polymer Sci. 1997;63(1):125-132.
Calvo P, Thomas C, Alonso MJ, Vila-Jato JL, Robinson JR. 
Study of the mechanism of interaction of poly (ϵ-caprolactone) 
nanocapsules with the cornea by confocal laser scanning 
microscopy. Int J Pharm. 1994;103(3):283-291.
Chakraborty SP, Sahu SK, Pramanik P, Roy S. In vitro 
antimicrobial activity of nanoconjugated vancomycin against 
drug resistant Staphylococcus aureus. Int J Pharm. 2012;436(1-
2):659-676.
Das S, Suresh, PK. Drug delivery to eye: Special reference to 
nanoparticles. Int J Drug Deliv. 2010;2(1):12-21.
De Campos AM, Sánchez A, Alonso MJ. Chitosan nanoparticles: 
a new vehicle for the improvement of the delivery of drugs to 
the ocular surface. Application to cyclosporin A. Int J Pharm. 
2001;224(1-2):159-168.
Di Colo G, Zambito Y, Burgalassi S, Nardini I, Saettone 
MF. Effect of chitosan and of N-carboxymethylchitosan on 
intraocular penetration of topically applied ofloxacin. Int J 
Pharm. 2004;273(1-2):37-44.
Duxfield L, Sultana R, Wang R, Englebretsen V, Deo S, 
Rupenthal ID, Al-Kassas R. Ocular delivery systems for topical 
application of anti-infective agents. Drug Dev Ind Pharm. 
2016;42(1):1-11.
Fan W, Yan W, Xu Z, Ni H. Formation mechanism of 
monodisperse, low molecular weight chitosan nanoparticles 
by ionic gelation technique. Colloids Surf B Biointerfaces. 
2012;90:21-27.
Felt O, Furrer P, Mayer JM, Plazonnet B, Buri P, Gurny 
R. Topical use of chitosan in ophthalmology: tolerance 
assessment and evaluation of precorneal retention. Int J Pharm. 
1999;180(2):185-193.
Hirano S, Seino H, et al. Bio-compatibility of chitosan by oral 
and intravenous administrations. Abstracts of papers of the 
American Chemical Society. Washington, DC; 1988.
Lang JC. Ocular drug delivery conventional ocular formulations. 
Adv Drug Deliv Rev. 1995;16(1):39-43.
Maurice D, Mishima S. Ocular pharmacokinetics. Pharmacology 
of the Eye. Berlin Heidelberg: Springer; 1984. p.19-116.
Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad 
FJ, Khar RK. Chitosan-sodium alginate nanoparticles as 
submicroscopic reservoirs for ocular delivery: formulation, 
optimisation and in vitro characterisation. Eur J Pharm Bioph. 
2008;68(3):513-525.
Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK. Polymeric 
nanoparticulate system: a potential approach for ocular drug 
delivery. J Control Release. 2009;136(1):2-13.
Osato MS, Jensen HG, Trousdale MD, Bosso JA, Borrmann LR, 
Frank J, Akers P. The comparative in vitro activity of ofloxacin 
and selected ophthalmic antimicrobial agents against ocular 
bacterial isolates. Am J Ophthalmol. 1989;108(4):380-386.
Papageorgiou SK, Kouvelos EP, Favvas EP, Sapalidis AA, 
Romanos GE, Katsaros FK. Metal-carboxylate interactions 
in metal-alginate complexes studied with FTIR spectroscopy. 
Carbohydr Res. 2010;345(4):469-473.
Reimondez-Troitiño S, Csaba N, Alonso MJ, de la Fuente M. 
Nanotherapies for the treatment of ocular diseases. Eur J Pharm 
Biopharm. 2015;95(Pt B):279-293.
Sahoo S, Chakraborti CK, Behera PK. FTIR and Raman 
spectroscopic investigations of Ofloxacin/Carbopol940 
mucoadhesive suspension. Int J PharmTech Res. 2012;4(1):382-
391.
Sahoo SK, Dilnawaz F, Krishnakumar Sl. Nanotechnology in 
ocular drug delivery. Drug Discov Today. 2008;13(3):144-151.
Sechoy O, Tissié G, Sébastian C, Maurin F, Driot JY, Trinquand 
C. A new long acting ophthalmic formulation of carteolol 
containing alginic acid. Int J Pharm. 2000;207(1):109-116.
Singh J, Dutta P. Preparation, antibacterial and physicochemical 
behavior of chitosan/ofloxacin complexes. Int J Polymeric 
Mater. 2010;59(10):793-807.
Sultana Y, Jain R, Aqil M, Ali A. Review of ocular drug delivery. 
Curr Drug Deliv. 2006;3(2):207-217.
S. Taghe, S. Mirzaeei
Braz. J. Pharm. Sci. 2019;55:e17105Page 12 / 12
Takeuchi H, Yamamoto H, Niwa T, Hino T, Kawashima 
Y. Enteral absorption of insulin in rats from mucoadhesive 
chitosan-coated liposomes. Pharm Res. 1996;13(6):896-901.
Thakur RR, Kashiv M. Modern delivery systems for ocular 
drug formulations: a comparative overview WRT conventional 
dosage form. Int J Res Pharm Biomed Sci. 2011;2:8-18.
Urtti A, Pipkin AD, ROrk JD, Sendo T, Finne U, Repta AJ. 
Controlled drug delivery devices for experimental ocular studies 
with timolol 2. Ocular and systemic absorption in rabbits. Int J 
Pharm. 1990;61(3):241-249.
Vårum KM, Myhr MM, Hjerde RJ, Smidsrød O. In vitro 
degradation rates of partially N-acetylated chitosans in human 
serum. Carbohydr Res. 1997;299(1):99-101.
Wu Y, Yang W, Wang C, Hu J, Fu S. Chitosan nanoparticles as 
a novel delivery system for ammonium glycyrrhizinate. Int J 
Pharm. 2005;295(1):235-245.
Yan XL, Khor E, Lim LY. Chitosan‐alginate films prepared with 
chitosans of different molecular weights. J Biomed Mater Res. 
2001;58(4):358-365.
Received for publication on 13th March 2017
Accepted for publication on 12th June 2018
This is an open-access article distributed under the terms of the Creative Commons Attribution License.
